Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Noemí Reguart

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Cancer Letters|March 8, 2021
MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescenceMarta Gabasa, Evette S Radisky, Rafael Ikemori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.
Oncotarget|December 8, 2016
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutationsAndrés F Cardona, Leonardo Rojas, Beatriz Wills, et al.
Cancer Research|May 11, 2017
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and MelanomaAleix Prat, Alejandro Navarro, Laia Paré, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Clinical Chemistry|January 12, 2017
Identification of <i>ALK</i>, <i>ROS1</i>, and <i>RET</i> Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer PatientsNoemí Reguart, Cristina Teixidó, Ana Giménez-Capitán, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patientsJoana Vidal, Sergi Clavé, Silvia de Muga, et al.
Lung Cancer (Amsterdam, Netherlands)|July 25, 2025
Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)Noemí Reguart, Laura Sampietro-Colom, Òscar Juan-Vidal, et al.
The Lancet. Oncology|September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trialJordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Cancer Letters|March 8, 2021
MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescenceMarta Gabasa, Evette S Radisky, Rafael Ikemori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2026
First-Line Sacituzumab Govitecan Plus Pembrolizumab and Carboplatin in Metastatic Non-Small Cell Lung Cancer: Nonsquamous and Squamous Cohorts of the EVOKE-02 StudyJhanelle E Gray, Joel W Neal, Jyoti D Patel, et al.
Oncotarget|December 8, 2016
BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutationsAndrés F Cardona, Leonardo Rojas, Beatriz Wills, et al.
Cancer Research|May 11, 2017
Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and MelanomaAleix Prat, Alejandro Navarro, Laia Paré, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 31, 2025
First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS Less Than 50% and More Than or Equal to 50% Cohorts of the EVOKE-02 StudyMartin Reck, Jyoti D Patel, Jhanelle E Gray, et al.
Cancer Treatment Reviews|June 24, 2014
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitorsChristian Rolfo, Elisa Giovannetti, David S Hong, et al.
Clinical Chemistry|January 12, 2017
Identification of <i>ALK</i>, <i>ROS1</i>, and <i>RET</i> Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer PatientsNoemí Reguart, Cristina Teixidó, Ana Giménez-Capitán, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 14, 2014
Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patientsJoana Vidal, Sergi Clavé, Silvia de Muga, et al.
Lung Cancer (Amsterdam, Netherlands)|July 25, 2025
Characterization and economic burden of KRASG12C-mutant lung cancer in real-world Spanish practice: a retrospective observational study (SILK study)Noemí Reguart, Laura Sampietro-Colom, Òscar Juan-Vidal, et al.
The Lancet. Oncology|September 4, 2025
Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trialJordi Remon, Paolo Bironzo, Nicolas Girard, et al.
Pageof 8